avastin

Showing 15 posts of 94 posts found.

screen_shot_2012-04-27_at_10

Novartis right to challenge NHS on Avastin use – ABPI chief

April 27, 2012
Sales and Marketing ABPI, Lucentis, Whitehead, avastin, wet AMD

The ABPI has declared its support for Novartis in its legal challenge against off-label prescribing in England.The pharma company is …

GMC won’t relax off-label prescribing guidelines

April 25, 2012
Sales and Marketing GMC, Lucentis, Novartis, Roche, avastin, off label, off-label

The GMC has decided not to relax guidelines on off-label prescribing when a licensed alternative exists. The GMC’s current rules …

Lucentis image

Charity challenges government on Avastin for wet AMD

April 24, 2012
Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …

Government to speed up access to new cancer drugs

April 24, 2012
Sales and Marketing CDF, Cancer, Roche, UK, avastin, government, sha

Access to England’s Cancer Drugs Fund will be speeded up, ministers have confirmed.  Currently, it can take a number of …

avastin

NICE rejects Avastin for breast cancer

April 18, 2012
Sales and Marketing EMA, NICE, Roche, avastin, breast cancer

In a blow for Roche, NICE has turned down its cancer drug Avastin because of ‘too many uncertainties’ over cost …

Access to new cancer drugs limited in Brazil and Mexico

April 13, 2012
Sales and Marketing Brazil, Cancer, Mexico, avastin, emerging markets

Between one-quarter and one-third of patients in Brazil and Mexico who are eligible for treatment with new cancer drugs do …

GMC guidance on off-label drug use delayed

March 19, 2012
Sales and Marketing GMC, Lucentis, avastin, off label, off-label, prescribing

The General Medical Council has delayed the release of new guidance for off-label prescribing. The doctors’ regulator was expected to …

caprelsa image

Major new drugs for 2012

March 9, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Caprelsa, Eylea, Manjor new drugs, Xalkori, Zelboraf, avastin, inlyta

 Renal cell carcinoma Pfizer’s Inlyta (axitinib) has been approved as second line treatment for renal cell carcinoma. The drug is …

Avastin picture

Avastin now available in UK for ovarian cancer

January 17, 2012
Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Roche, avastin

Roche’s Avastin is now available as a treatment for women with ovarian cancer in the UK. Avastin (bevacizumab) can now …

p0024

Avastin gains EU licence for ovarian cancer

January 3, 2012
Sales and Marketing Roche, avastin, ovarian

Roche’s Avastin has been granted a new European licence to treat ovarian cancer, which could help offset falling sales of …

Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Avastin picture

FDA pulls Roche’s Avastin for breast cancer

November 21, 2011
Research and Development, Sales and Marketing FDA, Roche, avastin

The FDA has pulled Avastin’s breast cancer licence in the US after the drug failed to prove its safety and …

Avastin pack shot

FDA’s rejection of Avastin creates conflict

October 31, 2011
Research and Development, Sales and Marketing FDA, avastin, breast cancer

Oncology experts have expressed concern at the FDA’s rejection of Roche’s Avastin for the treatment of advanced breast cancer. A …

Avastin

NHS regions back Avastin for eye disease

October 14, 2011
Sales and Marketing avastin

Regional NHS authorities around England are approving the use of Avastin instead of Lucentis for ophthalmology patients. A number of …

Latest content